Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Allogene Therapeutics, Inc.

Market Cap 670M 577M 531M 498M 936M 63.28B 945M 6.28B 2.45B 30.99B 2.51B 2.46B 107B P/E Ratio 2026 *
-2.76x
P/E Ratio 2027 * -2.59x
Enterprise Value 484M 417M 384M 360M 676M 45.73B 683M 4.54B 1.77B 22.4B 1.82B 1.78B 77.5B EV / Sales 2026 *
80,653x
EV / Sales 2027 * 43.8x
Free-Float
83.55%
Yield 2026 *
-
Yield 2027 * -
1 day+2.11%
1 week+4.86%
Current month-10.60%
1 month-3.00%
3 months-19.17%
6 months+31.97%
Current year+41.61%
1 week 1.75
Extreme 1.75
2.1
1 month 1.75
Extreme 1.75
2.32
Current year 1.31
Extreme 1.31
4.46
1 year 0.98
Extreme 0.9842
4.46
3 years 0.86
Extreme 0.8621
6.05
5 years 0.86
Extreme 0.8621
27.86
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 66 01/06/2018
Director of Finance/CFO 61 16/10/2023
Chief Tech/Sci/R&D Officer 49 28/02/2025
Director TitleAgeSince
Chairman 76 01/11/2017
Director/Board Member 66 01/06/2018
Director/Board Member 49 01/11/2017
Date Insider Type Main position Quantity % Market Cap.
04-21Sell

Controller/Auditor

9,586 0.0039%
03-31Sell

Chief Technology Officer

2,867 0.0013%
03-16Sell

Founder

47,763 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
+2.11%+4.86%+44.78%-60.97% 670M
-0.24%+0.18%+57.19%+108.17% 54.92B
-0.34%+3.51%+45.55%+40.16% 44.31B
+0.29%+6.20%-14.80%-19.65% 22.96B
-0.40%+3.49%-1.29%+387.06% 21.12B
-2.91%+0.27%+13.28%-36.73% 16.31B
-1.35%-2.24%+6.78%-41.18% 15.19B
-0.24%+2.44%+27.43%+177.49% 13.32B
+1.48%+9.81%+19.29% - 12.48B
+0.32%+2.81%+96.37%+213.49% 11.21B
Average -0.14%+2.97%+29.46%+85.31% 21.25B
Weighted average by Cap. -0.38%+2.86%+32.14%+94.68%

Financials

2026 *2027 *
Net sales 6K 5.17K 4.76K 4.46K 8.39K 567K 8.47K 56.27K 21.98K 278K 22.52K 22.04K 961K 12.97M 11.18M 10.29M 9.65M 18.13M 1.23B 18.32M 122M 47.52M 600M 48.68M 47.65M 2.08B
Net income -197M -169M -156M -146M -275M -18.58B -278M -1.84B -720M -9.1B -738M -722M -31.48B -227M -196M -180M -169M -318M -21.47B -321M -2.13B -832M -10.51B -852M -834M -36.38B
Net Debt -186M -160M -147M -138M -260M -17.55B -262M -1.74B -680M -8.59B -697M -682M -29.74B -101M -86.88M -79.96M -75.01M -141M -9.53B -142M -945M -369M -4.66B -378M -370M -16.14B
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
15/06/26 1.940 $ +2.11% 5,800,150
12/06/26 1.900 $ +1.06% 8,642,431
11/06/26 1.880 $ +5.62% 6,102,343
10/06/26 1.780 $ -2.20% 7,943,853
09/06/26 1.820 $ -1.62% 7,723,891
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.940USD
Average target price
8.485USD
Spread / Average Target
+337.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALLO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!